WO2010115202A3 - Procédés et compositions utilisables pour l'inhibition spécifique du gène kras par de l'arn double brin à extrémités franches - Google Patents

Procédés et compositions utilisables pour l'inhibition spécifique du gène kras par de l'arn double brin à extrémités franches Download PDF

Info

Publication number
WO2010115202A3
WO2010115202A3 PCT/US2010/029986 US2010029986W WO2010115202A3 WO 2010115202 A3 WO2010115202 A3 WO 2010115202A3 US 2010029986 W US2010029986 W US 2010029986W WO 2010115202 A3 WO2010115202 A3 WO 2010115202A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
kras
methods
stranded rna
specific inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/029986
Other languages
English (en)
Other versions
WO2010115202A2 (fr
Inventor
Bob D. Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dicerna Pharmaceuticals Inc
Original Assignee
Dicerna Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dicerna Pharmaceuticals Inc filed Critical Dicerna Pharmaceuticals Inc
Publication of WO2010115202A2 publication Critical patent/WO2010115202A2/fr
Publication of WO2010115202A3 publication Critical patent/WO2010115202A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés, des compositions et des procédés servant à faire baisser les niveaux d'ARN et de protéines KRAS cibles en faisant appel à des agents de type ARNsi à extrémités franches servant de substrat à l'enzyme Dicer (ARNsiD).
PCT/US2010/029986 2009-04-03 2010-04-05 Procédés et compositions utilisables pour l'inhibition spécifique du gène kras par de l'arn double brin à extrémités franches Ceased WO2010115202A2 (fr)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US16655909P 2009-04-03 2009-04-03
US16657809P 2009-04-03 2009-04-03
US61/166,578 2009-04-03
US61/166,559 2009-04-03
US17427909P 2009-04-30 2009-04-30
US17430609P 2009-04-30 2009-04-30
US61/174,279 2009-04-30
US61/174,306 2009-04-30
US25781009P 2009-11-03 2009-11-03
US25782009P 2009-11-03 2009-11-03
US61/257,810 2009-11-03
US61/257,820 2009-11-03

Publications (2)

Publication Number Publication Date
WO2010115202A2 WO2010115202A2 (fr) 2010-10-07
WO2010115202A3 true WO2010115202A3 (fr) 2010-12-09

Family

ID=42828982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/029986 Ceased WO2010115202A2 (fr) 2009-04-03 2010-04-05 Procédés et compositions utilisables pour l'inhibition spécifique du gène kras par de l'arn double brin à extrémités franches

Country Status (1)

Country Link
WO (1) WO2010115202A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2745373T3 (es) 2011-10-18 2020-03-02 Dicerna Pharmaceuticals Inc Lípidos catiónicos de amina y uso de los mismos
EP3736333A1 (fr) * 2012-05-02 2020-11-11 Arrowhead Pharmaceuticals, Inc. Compositions organiques pour traiter des maladies associées à kras
EP2968149B1 (fr) 2013-03-14 2024-05-08 Dicerna Pharmaceuticals, Inc. Procédé de formulation d'un agent anionique
HK1255699A1 (zh) 2015-09-24 2019-08-23 Ionis Pharmaceuticals, Inc. Kras表达的调节剂
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
EP3554535A4 (fr) 2016-12-14 2020-10-21 Janssen Biotech, Inc. Domaines de fibronectine de type iii se liant à pd-l1
EP3554561B1 (fr) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Domaines de fibronectine de type iii à liaison au cd137
BR112019012154A2 (pt) 2016-12-14 2019-11-12 Janssen Biotech, Inc. domínios do tipo iii da fibronectina de ligação a cd8a
US11382966B2 (en) 2017-03-24 2022-07-12 Rigontec Gmbh Method for designing RIG-I ligands
AU2019218991A1 (en) 2018-02-12 2020-07-09 Lonza Sales Ag Methods and compositions for macrophage polarization
SG11202110174PA (en) * 2019-03-29 2021-10-28 Dicerna Pharmaceuticals Inc Compositions and methods for the treatment of kras associated diseases or disorders
WO2021076546A1 (fr) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Domaines de type iii de fibronectine de liaison à cd137
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
US12239710B2 (en) 2021-04-14 2025-03-04 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
IL307582A (en) 2021-04-14 2023-12-01 Aro Biotherapeutics Company CD71-binding domains of the fibronectin type
CA3214540A1 (fr) * 2021-04-22 2022-10-27 Pasi A. Janne Compositions et methodes pour traiter le cancer
EP4359536A4 (fr) * 2021-06-21 2025-12-03 Univ North Carolina Chapel Hill Molécules d'arnsi chimériques inversées et leurs procédés d'utilisation
US20240392293A1 (en) * 2021-09-02 2024-11-28 Molecular Axiom, Llc Compositions and methods for modulating kras expression

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020076696A1 (en) * 1996-11-08 2002-06-20 Haruma Kawaguchi Method for determination of specific nucleic acid sequence and a reagent therefor
US20040063111A1 (en) * 2000-08-25 2004-04-01 Toshikazu Shiba Method for protecting personal information
US20070088152A1 (en) * 2002-11-14 2007-04-19 Dharmacon Inc. siRNA targeting KRAS
US20070254850A1 (en) * 2002-10-30 2007-11-01 Judy Lieberman Methods for Treating and Preventing Apoptosis-Related Diseases Using Rna Interfering Agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020076696A1 (en) * 1996-11-08 2002-06-20 Haruma Kawaguchi Method for determination of specific nucleic acid sequence and a reagent therefor
US20040063111A1 (en) * 2000-08-25 2004-04-01 Toshikazu Shiba Method for protecting personal information
US20070254850A1 (en) * 2002-10-30 2007-11-01 Judy Lieberman Methods for Treating and Preventing Apoptosis-Related Diseases Using Rna Interfering Agents
US20070088152A1 (en) * 2002-11-14 2007-04-19 Dharmacon Inc. siRNA targeting KRAS

Also Published As

Publication number Publication date
WO2010115202A2 (fr) 2010-10-07

Similar Documents

Publication Publication Date Title
WO2010115206A3 (fr) Procédés et compositions pour l'inhibition spécifique de kras par de l'arn double brin asymétrique
WO2012006241A3 (fr) Procédés et compositions pour l'inhibition spécifique du récepteur des androgènes par arn double brin
WO2012006243A3 (fr) Procédés et compositions pour l'inhibition spécifique de bêta-caténine par arn double brin
WO2015003113A3 (fr) Procédé et composition pour l'inhibition spécifique de l'antitrypsine alpha-1 par un arn bicaténaire
WO2010141726A3 (fr) Agents de substrat dicer et de peptide, procédés pour leur inhibition spécifique de l'expression génique
WO2012145582A3 (fr) Procédés et compositions pour les inhibitions spécifiques d'egfr par un arn à double brin
MX2018013216A (es) Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
CA2792561C (fr) Compositions et procedes permettant d'inhiber l'expression du gene cd274/pd-l1
EA201792626A1 (ru) Композиции и способы для ингибирования экспрессии транстиретина
WO2009111658A3 (fr) Compositions et procédés pour inhiber l’expression des gènes eg5 et vegf
WO2009076400A3 (fr) Compositions et procédés permettant l'inhibition de l'expression du gène du facteur vii
WO2009129465A3 (fr) Compositions et méthodes d'inhibition de l'expression du gène xbp-1
WO2012135736A3 (fr) Modulation de l'expression du transducteur de signal et activateur de transcription 3 (stat3)
WO2010045384A3 (fr) Arn courts en épingles à cheveux destinés à inhiber l’expression des gènes
WO2012153193A3 (fr) Conjugués protéine-principe actif et leur procédé de préparation
WO2012027713A3 (fr) Compositions et méthodes d'inhibition de la snca
WO2011031896A3 (fr) Inhibiteurs de pi3 kinase et leurs utilisations
WO2010111626A3 (fr) Inhibiteurs de la poly(adp-ribose)polymérase (parp)
WO2016183009A3 (fr) Méthodes et compositions pour l'inhibition spécifique de l'antithrombine 3 (at3) par un arn bicaténaire
WO2008151631A3 (fr) Utilisation de courts oligonucléotides pour des expériences à redondance de réactif dans une analyse fonctionnelle d'arn
WO2011160052A3 (fr) Procédés et compositions associés à des arn-endonucléases spécifiques d'une séquence
WO2010028054A8 (fr) Compositions et procédés d'inhibition de l'expression d'un gène egfr mutant
WO2014093746A3 (fr) Procédés et compositions pour l'inhibition spécifique de ckap5 par un arn à double brin
WO2007106915A8 (fr) Anticorps à efgl 7 et leurs procédés d'utilisation
WO2013068850A3 (fr) Procédé pour la préparation de β-c-arylglucosides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10759545

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10759545

Country of ref document: EP

Kind code of ref document: A2